Lab at Satorius Life Science.Lab at Satorius Life Science.

Sartorius Sets Ambitious Growth Targets Through 2028

Sartorius, a leading biotech company, Friday outlined its ambitious growth plans for the coming years, aiming to significantly elevate its market position by 2028.

2024 Outlook: Robust Revenue Growth and High Profit Margins

For 2024, Sartorius is poised to increase its revenue in the mid to upper single-digit percentage range. This growth trajectory is underpinned by the company’s innovative approach and strong market demand for its biotechnology solutions. The company is not only focusing on revenue growth but also on profitability, targeting an operational profit margin of just over 30 percent. This balance of growth and profitability underscores Sartorius’s strategic approach to expanding its market share while maintaining financial health.

“2023 was a very unusual and challenging year in our industry. The customers’ destocking and other factors such as very weak demand in China had a longer and more pronounced business performance for longer and to a greater extent than originally forecast. Therefore we ended the past year with declining sales, although our profitability continued to improve due to an adjusted cost base profitability remained at a healthy level and above the pre-pandemic level due to an adjusted cost base. … As many customers are now further advanced with their warehouse optimizations, business has picked up since the end of the 3rd quarter, and we expect this trend to gradually increase over the course of 2024 should gradually strengthen over the course of 2024,”

said Sartorius CEO Joachim Kreuzburg on Friday.

Forecast for 2024: Group aims to increase sales in the mid to upper single-digit percentage range
and achieve an operating earnings margin of just over 30 percent

Debt Reduction and Capital Initiatives

A key component of Sartorius’s financial strategy is the rapid reduction of debt, leveraging its robust operational cash flow. The company is exploring additional capital measures to accelerate this process, reflecting a proactive approach to financial management and corporate responsibility.

Mid-term Ambitions: Sustained Growth and Increased Margins by 2028

Looking further ahead, Sartorius has set even more ambitious goals for 2028. The company anticipates an average annual revenue growth of over 10 percent, a clear indicator of its confidence in its long-term strategy and market opportunities. In terms of profitability, Sartorius aims to increase its earnings margin to around 34 percent by 2028, demonstrating its commitment to continuous improvement and shareholder value.

This strategic plan highlights Sartorius’s dedication to maintaining its position as a leader in the biotech industry, with a clear focus on sustainable growth, financial stability, and long-term profitability.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner